III. Contraindications

  1. Recent major bleeding

IV. Mechanism

  1. Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
  2. Inhibits Fibrinogen binding to Platelets

V. Dosing

  1. Non-ST elevation Myocardial Infarction (NSTEMI)
    1. Load: 25 mcg/kg over 5 min
    2. Infuse: 0.15 mcg/kg/min for up to 18 hours
      1. Slow rate to 0.075 mcg/kg/min if GFR <=60 ml/min

VI. Safety

  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation

Images: Related links to external sites (from Bing)

Related Studies

Ontology: tirofiban (C0247025)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C078823
SnomedCT 108981004, 386953003
LNC LP171644-0
English N-(butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine, tirofiban, tirofiban (medication), tirofiban [Chemical/Ingredient], TIROFIBAN, Tirofiban (product), Tirofiban (substance), Tirofiban
Spanish tirofibán (producto), tirofibán (sustancia), tirofibán

Ontology: Aggrastat (C0656369)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C078823
English Aggrastat, aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp & Dohme brand of tirofiban hydrochloride monohydrate, Merck brand of tirofiban hydrochloride monohydrate, Agrastat